Skip to main content

Ovid Therapeutics Inc. (OVID)

NASDAQ: OVID · Delayed Price · USD
3.34 -0.03 (-0.89%)
Sep 20, 2021 4:00 PM EDT - Market closed
Market Cap225.53M
Revenue (ttm)221.00M
Net Income (ttm)121.76M
Shares Out67.82M
EPS (ttm)1.81
PE Ratio1.85
Forward PE1.79
Dividendn/a
Ex-Dividend Daten/a
Volume194,659
Open3.33
Previous Close3.37
Day's Range3.30 - 3.43
52-Week Range2.25 - 6.98
Beta1.77
AnalystsBuy
Price Target4.75 (+42.2%)
Est. Earnings DateNov 11, 2021

About OVID

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase III clinical trial for the treatment of angelman syndrome in adults; and completed Phase II clinical trial for the treatment of fragile X syndrome in adolescent and young male adults. It is also developing OV935, a drug candidate, which has completed Phase II clinical trial for the treatment of cyclin-dependent kinase-lik...

IndustryBiotechnology
IPO DateMay 5, 2017
CEOJeremy Levin
Employees60
Stock ExchangeNASDAQ
Ticker SymbolOVID
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for OVID stock is "Buy." The 12-month stock price forecast is 4.75, which is an increase of 42.22% from the latest price.

Price Target
$4.75
(42.22% upside)
Analyst Consensus: Buy

News

Ovid Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights

NEW YORK, Aug. 16, 2021 (GLOBE NEWSWIRE) --  Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological dis...

1 month ago - GlobeNewsWire

A Trio of Magic Formula Stock Picks

In order to increase your chances of beating the market, one method is to choose stocks that rank highly according to the "Magic Formula" criteria.

Other symbols:DBDVNT
2 months ago - GuruFocus

Ovid Therapeutics Strengthens Board & Leadership Team to Focus Efforts on Expanding Its Neurosciences Capabilities

Dr. Michael Poole to Join the Board of Directors

2 months ago - GlobeNewsWire

Ovid Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference

NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological...

2 months ago - GlobeNewsWire

Ovid Therapeutics Appoints Dr. Joy A. Cavagnaro and Dr. Bruce A.

NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological ...

3 months ago - GlobeNewsWire

3 Biotech Stocks to Keep an Eye On Amid the Coronavirus Mayhem

3 Biotech Stocks to Keep an Eye On Amid the Coronavirus Mayhem

Other symbols:REGNRGEN
4 months ago - Zacks Investment Research

Ovid Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neur...

4 months ago - GlobeNewsWire

Ovid Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference

NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological ...

4 months ago - GlobeNewsWire

HMNY Stock & 7 Other Reddit Penny Stocks Hoping for a Takeover

The odds of bankrupt HMNY stock getting acquired may be slim, but for these seven other Reddit penny stocks it's definitely a possibility. The post HMNY Stock & 7 Other Reddit Penny Stocks Hoping for a ...

4 months ago - InvestorPlace

Ovid Therapeutics Stops Gaboxadol Development Citing Limited Efficacy In Rare Neurological Conditions

Ovid Therapeutics Inc (NASDAQ: OVID) has announced to discontinue the development of OV101 (gaboxadol), a delta (δ)-selective GABAA receptor agonist, in Angelman syndrome and Fragile X syndrome. The com...

5 months ago - Benzinga

4 Biotech Penny Stocks To Watch That Are Heating Up This Month

Biotech penny stocks are all the rage; should you check these four out? The post 4 Biotech Penny Stocks To Watch That Are Heating Up This Month appeared first on Penny Stocks to Buy, Picks, News and Inf...

Other symbols:AIKIITRMTTOO
5 months ago - PennyStocks

8 Biotech Penny Stocks for Investors to Watch

Low-priced biotechs have sold off recently, but there could still be potential in these picks. Here are eight penny stocks to consider.

6 months ago - InvestorPlace

OVID Stock News: The Big Deal That Has Ovid Therapeutics Rocketing Higher Today

Ovid Therapeutics (OVID) stock is soaring higher on Wednesday after announcing a massive deal with Takeda Pharmaceutical (TKPHF). The post OVID Stock News: The Big Deal That Has Ovid Therapeutics Rocket...

6 months ago - InvestorPlace

Why Ovid, KemPharm, Sorrento, Aquestive Are Rallying

Ovid Therapeutics Inc. (NASDAQ: OVID), KemPharm Inc (NASDAQ: KMPH), Aquestive Therapeutics Inc (NASDAQ: AQST) and Sorrento Therapeutics, Inc. (NASDAQ: SRNE) were among the health care gainers in Wednesd...

Other symbols:KMPHSRNEAQST
6 months ago - Benzinga

Ovid Shares Rally On Soticlestat Development Pact With Takeda In Rare Epilepsy Syndromes

Takeda Pharmaceutical Co Ltd (NYSSE: TAK) has agreed to secure global rights from Ovid Therapeutics Inc (NASDAQ: OVID) for soticlestat (TAK-935/OV935) for the treatment of developmental and epileptic en...

Other symbols:TAK
6 months ago - Benzinga

Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Chi...

OSAKA, Japan & NEW YORK--(BUSINESS WIRE)--Takeda has entered into an exclusive agreement with partner Ovid Therapeutics to develop and commercialize the investigational medicine soticlestat.

Other symbols:TAK
6 months ago - Business Wire

Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index

NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological...

9 months ago - GlobeNewsWire

Ovid Therapeutics News: Why OVID Stock Is Plunging 55% Today

Ovid Therapeutics (OVID) news for Wednesday concerning results from a recent clinical trial have OVID stock taking a beating. The post Ovid Therapeutics News: Why OVID Stock Is Plunging 55% Today appear...

9 months ago - InvestorPlace

Why Ovid Therapeutics Stock Is Imploding Today

The company reported disappointing results from a late-stage clinical trial.

9 months ago - The Motley Fool

Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Me...

NEW YORK, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological...

9 months ago - GlobeNewsWire

Are Options Traders Betting on a Big Move in Ovid Therapeutics (OVID) Stock?

Investors need to pay close attention to Ovid Therapeutics (OVID) stock based on the movements in the options market lately.

9 months ago - Zacks Investment Research

Ovid Therapeutics to Present at the American Epilepsy Society (AES) 2020 Virtual Congress

Abstracts will be presented from the TAK-935/OV935 (soticlestat) clinical development program in Dravet syndrome or Lennox-Gastaut syndrome (Phase 2 ELEKTRA study) and OV101 (gaboxadol) clinical develop...

9 months ago - GlobeNewsWire

Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological...

10 months ago - GlobeNewsWire

Ovid Therapeutics to Host Educational Webinar on Angelman Syndrome and OV101 Development Program

NEW YORK, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological...

11 months ago - GlobeNewsWire

Ovid Therapeutics to Present at the Child Neurology Society/International Child Neurology Association (CNS/ICNA) Virt...

NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological...

11 months ago - GlobeNewsWire